Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYE103 vs ranibizumab in diabetic macular edema
jRCT2071250032Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of restoret in diabetic macular edema (DME) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline best-corrected visual acuity at Week 52. Started Aug 2025; status: active, not recruiting.
02
Drugs
restoret
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2071250032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250032.